| Autor: |
Inmaculada Domínguez-Mozo, María, González-Suárez, Inés, María Villar, Luisa, Costa-Frossard, Lucienne, Villarrubia, Noelia, Aladro, Yolanda, Pilo, Belén, Montalbán, Xavier, Comabella, Manuel, Casanova-Peño, Ignacio, Luisa Martínez-Ginés, María, García-Domínguez, Jose Manuel, Ángel García-Martínez, María, Arroyo, Rafael, Álvarez-Lafuente, Roberto |
| Předmět: |
|
| Zdroj: |
Frontiers in Immunology; 2023, p01-09, 9p |
| Abstrakt: |
Background: Epstein-Barr virus (EBV) and human herpesvirus 6 (HHV-6) have been associated with multiple sclerosis (MS). Teriflunomide is an oral disease- modifying therapy approved for treatment of relapsing forms of MS. In the preclinical Theiler's murine encephalitis virus model of MS, the drug demonstrated an increased rate of viral clearance versus the vehicle placebo. Furthermore, teriflunomide inhibits lytic EBV infection in vitro. Objective: 1. To evaluate the humoral response against EBV and HHV-6 prior to teriflunomide treatment and 6 months later. 2. To correlate the variation in the humoral response against EBV and HHV-6 with the clinical and radiological response after 24 months of treatment with teriflunomide. 3. To analyze the utility of different demographic, clinical, radiological, and environmental data to identify early biomarkers of response to teriflunomide. Methods: A total of 11 MS patients (62 women; mean age: 43.4 years) with one serum prior to teriflunomide onset and another serum sample 6 months later were recruited. A total of 8 had been treated for at least 24 months, 13 had stopped teriflunomide before 24 months, and 8 were currently under teriflunomide therapy but with less than 24 months of follow-up. We analyzed the levels of the viral antibodies titers abovementioned in serum samples with ELISA commercial kits, and the levels of serum neurofilament light chain (Nf-L). Results: Antiviral antibody titers decreased for EBNA-1 IgG (74.3%), VCA IgG (69%), HHV-6 IgG (6.4%), and HHV-6 IgM (73.3%) after 6 months of teriflunomide. VCA IgG titers at baseline correlated with Nf-L levels measured at the same time (r = .221; p = .28) and 6 months later (r = .24; p = .17). We found that higher EBNA-1 titers (p = .1) and a higher age (p = .4) at baseline were associated with NEDA-3 conditions. Thus, 77.8% of patients with EBNA-1 >23. AU and >42.8 years (P5 values) were NEDA-3. Conclusion: Treatment with teriflunomide was associated with a reduction of the levels of IgG antibody titers against EBV and HHV-6. Furthermore, higher EBNA-1 IgG titers prior to teriflunomide initiation were associated with a better clinical response. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
